| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-1736 |
| P698 | PubMed publication ID | 20924102 |
| P50 | author | Mark J. Smyth | Q38544864 |
| Christoph Loddenkemper | Q47160857 | ||
| Alf Hamann | Q47160923 | ||
| P2093 | author name string | Jochen Huehn | |
| Shin Foong Ngiow | |||
| Tim Sparwasser | |||
| Katharina Lahl | |||
| Michele W L Teng | |||
| Christian T Mayer | |||
| Katjana Klages | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7788-7799 | |
| P577 | publication date | 2010-10-05 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma | |
| P478 | volume | 70 |
| Q42775633 | A mathematical model of immune activation with a unified self-nonself concept |
| Q47643448 | A nonimmune function of T cells in promoting lung tumor progression |
| Q34641181 | Advantages of Foxp3(+) regulatory T cell depletion using DEREG mice. |
| Q41242778 | An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects |
| Q36718256 | Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes |
| Q36060263 | Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression |
| Q35666506 | Beyond adjuvants: immunomodulation strategies to enhance T cell immunity |
| Q40066040 | Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment |
| Q88109417 | Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression |
| Q58861245 | CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells |
| Q40160482 | CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation |
| Q92970937 | Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment |
| Q86199528 | Chemokines in cancer |
| Q83300021 | Co-stimulation by dendritic cells maintains the peripheral pool of Tregs |
| Q52603627 | Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. |
| Q36828834 | Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein |
| Q37832967 | Contribution of the immune system to the chemotherapeutic response. |
| Q38815289 | Cytotoxic CD8+ T cell ablation enhances the capacity of regulatory T cells to delay viral elimination in Theiler's murine encephalomyelitis. |
| Q40169924 | Depletion of FoxP3(+) Tregs improves control of larval Echinococcus multilocularis infection by promoting co-stimulation and Th1/17 immunity |
| Q45716103 | Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. |
| Q34162856 | Differential control of immune cell homeostasis by Foxp3(+) regulatory T cells in murine peripheral lymph nodes and spleen |
| Q89794035 | Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy |
| Q38525024 | Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression |
| Q37197925 | Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion |
| Q99557499 | Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity |
| Q24629841 | Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma |
| Q53951581 | Few Foxp3⁺ regulatory T cells are sufficient to protect adult mice from lethal autoimmunity. |
| Q41694733 | Foxp3+ regulatory T-cell homeostasis quantitatively differs in murine peripheral lymph nodes and spleen. |
| Q26865532 | From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors |
| Q35010258 | GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells |
| Q26825120 | Galectin-1 research in T cell immunity: past, present and future |
| Q43090164 | Home sweet home: the tumor microenvironment as a haven for regulatory T cells. |
| Q41678975 | Hypoxia-inducible factors: a central link between inflammation and cancer |
| Q57805539 | Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types |
| Q89556686 | Immune crosstalk in cancer progression and metastatic spread: a complex conversation |
| Q36024656 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). |
| Q38161367 | Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines |
| Q27002646 | Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy |
| Q42701148 | Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy |
| Q90050590 | Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges |
| Q28607232 | Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model |
| Q50051034 | Improving immune-vascular crosstalk for cancer immunotherapy. |
| Q43117942 | Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells |
| Q43916071 | Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer |
| Q88499080 | Integrative Pharmacology: Advancing Development of Effective Immunotherapies |
| Q37259195 | Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation |
| Q50974260 | Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells |
| Q47396944 | Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8(+) T response. |
| Q36073220 | Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity |
| Q38038176 | Lessons from cancer immunoediting in cutaneous melanoma |
| Q34661115 | Lineage stability and phenotypic plasticity of Foxp3⁺ regulatory T cells. |
| Q57571845 | Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma |
| Q36972613 | Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients |
| Q39109245 | Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases |
| Q37892595 | Melanoma vaccines: developments over the past 10 years. |
| Q38097311 | Modulating T regulatory cells in cancer: how close are we? |
| Q28072712 | Monitoring of the Immune Dysfunction in Cancer Patients |
| Q42200876 | Mouse cytomegalovirus infection overrules T regulatory cell suppression on natural killer cells. |
| Q37963294 | Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses |
| Q38123165 | Natural and induced T regulatory cells in cancer. |
| Q38635328 | Negative Correlation between Circulating CD4+FOXP3+CD127- Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role |
| Q92827446 | Neoantigen vaccine: an emerging tumor immunotherapy |
| Q34643612 | Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth |
| Q39472057 | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice |
| Q34408309 | Optimal isolation of functional Foxp3+ induced regulatory T cells using DEREG mice |
| Q38262255 | Overcoming tumor-mediated immunosuppression |
| Q92101831 | Overproduction of IL-2 by Cbl-b deficient CD4+ T cells provides resistance against regulatory T cells |
| Q33743876 | Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination |
| Q26783675 | Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis |
| Q46264331 | Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model |
| Q33606144 | Rational combinations of immunotherapeutics that target discrete pathways |
| Q45047171 | Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer |
| Q26991447 | Regulatory T cell: a protection for tumour cells |
| Q37272005 | Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation |
| Q85797220 | Regulatory T cells in B-cell-deficient and wild-type mice differ functionally and in expression of cell surface markers |
| Q36038429 | Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer |
| Q91586245 | Requirement of Mitochondrial Transcription Factor A in Tissue-Resident Regulatory T Cell Maintenance and Function |
| Q42186082 | SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines |
| Q34369526 | SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ |
| Q39379300 | Skin Immunity. |
| Q41400520 | T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion |
| Q33886184 | TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo |
| Q38985243 | TREG Cells in Cancer: Beyond Classical Immunological Control |
| Q57793164 | Targeted killing of TNFR2-expressing tumor cells and T by TNFR2 antagonistic antibodies in advanced Sézary syndrome |
| Q89388664 | Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma |
| Q57160066 | Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity |
| Q38875021 | Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. |
| Q41935730 | Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination |
| Q34164169 | Targeting regulatory T cells to improve vaccine immunogenicity in early life |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q38289041 | Targeting the bone marrow microenvironment in multiple myeloma. |
| Q99418746 | Targeting the epigenetic regulation of antitumour immunity |
| Q47194123 | Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? |
| Q33736218 | The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment |
| Q90706071 | The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction |
| Q35176439 | The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells |
| Q38288116 | The delicate balance of melanoma immunotherapy |
| Q51084408 | The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs |
| Q36118884 | The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists. |
| Q51237415 | The expression of Foxp3 and TLR4 in cervical cancer: association with immune escape and clinical pathology |
| Q36694921 | The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity |
| Q91293267 | The multifaceted Foxp3fgfp allele enhances spontaneous and therapeutic immune surveillance of cancer in mice |
| Q35931795 | The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells |
| Q38357137 | The role of oncolytic virus immunotherapies to subvert cancer immune evasion |
| Q41592594 | Therapeutic vaccine to cure large mouse hepatocellular carcinomas |
| Q64071046 | Therapy with CD4CD25 T regulatory cells - should we be afraid of cancer? |
| Q91208631 | Tissue Site and the Cancer Immunity Cycle |
| Q83730992 | Transcriptional programming in the immune system: report on the International Workshop of the Transregio TR52, November 17-20, 2010 in Würzburg, Germany |
| Q39254820 | Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells |
| Q37660771 | Transient Treg depletion enhances therapeutic anti-cancer vaccination. |
| Q37246484 | Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy |
| Q26772335 | Translating Treg Therapy in Humanized Mice |
| Q51799863 | Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. |
| Q40011543 | Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin |
| Q26822874 | Tregs in infection and vaccinology: heroes or traitors? |
| Q55386131 | Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. |
| Q39198945 | Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis |
| Q56891314 | Tumor-Specific Inhibition of Vaccination by Distant Untreated Tumor Sites |
| Q39271720 | Tumor-associated Glycans and Tregs in Immunogenicity of an Autologous Cell-based Vaccine |
| Q37175625 | Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma |
| Q36602010 | Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. |
| Q39393666 | Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. |
| Q64108546 | Turning the Tide Against Regulatory T Cells |
| Q64967202 | YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. |
Search more.